Skip to main content
Premium Trial:

Request an Annual Quote

FTC Asks Varian, Agilent for More Information

NEW YORK (GenomeWeb News) – The US Federal Trade Commission has asked Varian and Agilent Technologies for additional information in connection with Agilent's proposed $1.5 billion acquisition of Varian.

Palo Alto, Calif.-based Varian said in a filing with the US Securities and Exchange Commission this week that the FTC asked both firms for more information, but it did not provide further details. The company said that the request "extends the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after Agilent and Varian have substantially complied with the second request unless that period is extended voluntarily by the parties or terminated sooner by the FTC."

Agilent and Varian inked the merger agreement in late July. The firms said at the time that they expect to close the deal by the end of 2009.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.